Wall Street analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to announce ($0.20) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Celldex Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.20). Celldex Therapeutics reported earnings per share of ($0.30) during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The company is expected to announce its next quarterly earnings report on Tuesday, March 13th.
According to Zacks, analysts expect that Celldex Therapeutics will report full-year earnings of ($0.93) per share for the current fiscal year, with EPS estimates ranging from ($1.07) to ($0.86). For the next financial year, analysts forecast that the business will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.09) to ($0.59). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Celldex Therapeutics.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The business had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $1.30 million. During the same quarter in the prior year, the business posted ($0.29) earnings per share. Celldex Therapeutics’s revenue was up 77.3% compared to the same quarter last year.
Celldex Therapeutics (NASDAQ:CLDX) traded down $0.04 on Thursday, reaching $2.86. 823,100 shares of the company traded hands, compared to its average volume of 1,666,621. Celldex Therapeutics has a 1-year low of $2.20 and a 1-year high of $4.07.
A number of hedge funds and other institutional investors have recently modified their holdings of CLDX. Cubist Systematic Strategies LLC acquired a new position in Celldex Therapeutics during the third quarter worth about $101,000. BB&T Securities LLC acquired a new position in Celldex Therapeutics during the second quarter worth about $117,000. OxFORD Asset Management LLP acquired a new position in Celldex Therapeutics during the third quarter worth about $122,000. Voya Investment Management LLC raised its stake in Celldex Therapeutics by 17.4% during the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 7,499 shares in the last quarter. Finally, Overbrook Management Corp acquired a new position in Celldex Therapeutics during the second quarter worth about $139,000. 52.55% of the stock is owned by hedge funds and other institutional investors.
WARNING: This report was reported by Week Herald and is the property of of Week Herald. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://weekherald.com/2017/12/30/zacks-analysts-expect-celldex-therapeutics-inc-cldx-will-post-earnings-of-0-20-per-share.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.